Last updated on February 2018

A Randomised Trial of Dolutegravir (DTG)-Based Antiretroviral Therapy vs. Standard of Care (SOC) in Children With HIV Infection Starting First-line or Switching to Second-line ART


Brief description of study

A new anti-HIV medicine (Dolutegravir) combined with 2 currently used anti-HIV medicines is non-inferior to the standard combination of medicines used in terms of efficacy and better in terms of toxicity.

Clinical Study Identifier: NCT02259127

Find a site near you

Start Over

PHRU

Soweto, South Africa
8.87miles
  Connect »